131 related articles for article (PubMed ID: 11774101)
1. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
5. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
8. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
9. [Phase I study of capecitabine with concurrent radiotherapy in early-stage nasopharyngeal carcinoma].
Guo L; Lin HX; Li FY; Li Q; Qiu F; Luo DH; Guo X; Hong MH
Zhonghua Zhong Liu Za Zhi; 2004 Apr; 26(4):250-3. PubMed ID: 15312392
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Hoff PM; Pazdur R; Lassere Y; Carter S; Samid D; Polito D; Abbruzzese JL
J Clin Oncol; 2004 Jun; 22(11):2078-83. PubMed ID: 15169794
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer.
Chua D; Wei WI; Sham JS; Au GK
Jpn J Clin Oncol; 2008 Apr; 38(4):244-9. PubMed ID: 18407933
[TBL] [Abstract][Full Text] [Related]
12. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
13. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
[TBL] [Abstract][Full Text] [Related]
14. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine for treatment of advanced hepatocellular carcinoma.
von Delius S; Lersch C; Mayr M; Stock K; Schulte-Frohlinde E; Schmid RM; Eckel F
Hepatogastroenterology; 2007 Dec; 54(80):2310-4. PubMed ID: 18265654
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.
Jenkins AD; Ramondetta LM; Sun C; Johnston T; Wolf JK; Bodurka DC; Brown J; Atkinson EN; Levenback C
Gynecol Oncol; 2005 Jun; 97(3):840-4. PubMed ID: 15882895
[TBL] [Abstract][Full Text] [Related]
18. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.
Bajetta E; Procopio G; Celio L; Gattinoni L; Della Torre S; Mariani L; Catena L; Ricotta R; Longarini R; Zilembo N; Buzzoni R
J Clin Oncol; 2005 Apr; 23(10):2155-61. PubMed ID: 15710946
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
